Anellovirus genome quantification as a biomarker of immune suppression
AssigneesInstitut Pasteur, Universite Paris Descartes, Assistance Publique-Hopitaux de Paris, Pathoquest, Ecole Nationale Veterinaire D'Alfort
InventorsMarc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
Claims45
A method of stimulating the immune system of a human subject in need thereof, comprising
- 1) obtaining a blood sample from the human subject,
- 2) measuring the level of anellovirus DNA in the sample by a method comprising detecting Torque teno virus (TTV) DNA, Torque teno midi virus (TTMDV) DNA, and Torque teno mini virus (TTMV) DNA,
- 3) calculating the ratio of anelloviral sequences to the total number of sequences present in the sample, wherein said measured ratio is higher than 0.2×10−4, and
- 4) administering a treatment to stimulate the immune system of the human subject.
A method of immunosuppressing the immune system of a human subject in need thereof, comprising
- 1) obtaining a blood sample from the human subject,
- 2) measuring the level of anellovirus DNA in the sample by a method comprising detecting Torque teno virus (TTV) DNA, Torque teno midi virus (TTMDV) DNA, and Torque teno mini virus (TTMV) DNA,
- 3) calculating the ratio of anelloviral sequences to the total number of sequences present in the sample, wherein said measured ratio is lower than 0.2×10−4, and
- 4) administering a treatment to suppress the immune system of the human subject.
A method comprising
- 1) obtaining a blood sample from a human subject undergoing an immunomodulation treatment,
- 2) measuring the level of anellovirus DNA in the sample by a method comprising detecting Torque teno virus (TTV) DNA, Torque teno midi virus (TTMDV) DNA, and Torque teno mini virus (TTMV) DNA,
- 3) calculating the ratio of anelloviral sequences to the total number of sequences present in the sample, wherein said measured ratio is about 0.2×10−4, and
- 4) continuing the immunomodulation treatment.
Dependencies are inferred from the claim text.